MANE
Veradermics, Incorporated
NYSE · usd
Veradermics, Incorporated (MANE) trades at $138.87 (+0.06%) as of 2:05:20 PM EDT on Oct 26, 2026, +19.52% over the past month. Market cap is $5.8B, with 4.7 days to cover in short interest.
Stock performance
How Veradermics, Incorporated (MANE) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.40%
- 1W
- +13.94%
- 1M
- +19.52%
- YTD
- +269.09%
- 1Y
- +269.09%
- 52-wk range
- $32.00 – $141.75
Key statistics
Today's trading snapshot for MANE: day range, open, previous close, volume and market cap.
- Day range
- $135.61 – $140.80
- Open
- $136.74
- Prev close
- $138.78
- Volume
- 216.91K
- Market cap
- $5.8B
- Shares out
- 41.78M
8-K filings
Material corporate events Veradermics, Incorporated has disclosed to the SEC on Form 8-K.
- Business updateOct 19, 2026
On October 19, 2026, Veradermics, Incorporated issued a press release announcing positive topline data from the Phase 3 clinical trial, Study '304' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.
- Investor presentationJul 15, 2026
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation the Company presented on the conference call and webcast is furnished as Exhibit 99.2 to this Current Report on Form 8-K, and both are incorporated by reference herein.
- Public offeringMay 1, 2026
On May 1, 2026, Veradermics, Incorporated (the "Company") closed its underwritten public offering (the "Public Offering") of 3,843,790 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), at a public offering price of $100.00 per share, pursuant to the Company's registration statements on Form S-1 (File Nos. 333-295356 and 333-295420). In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 576,568 shares of Common Stock at the public offering price, less underwriting discounts and commissions.
- Investor presentationApr 27, 2026
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the presentation the Company presented on the conference call and webcast is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
- Preliminary resultsApr 27, 2026
Veradermics, Incorporated (the "Company") reports that it had a preliminary unaudited amount of cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. This amount is preliminary and unaudited and is subject to completion of the Company's financial closing procedures.
MANE short interest
How heavily MANE is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.7
- Short interest
- 4.24M
- Avg volume
- 907.03K
As of · reported to FINRA twice monthly.
Frequently asked questions
What is the Veradermics, Incorporated (MANE) stock price today?
Veradermics, Incorporated (MANE) is trading at $138.87 (+0.06% on the day) as of 2:05:20 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Veradermics, Incorporated?
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions.
What is the short interest in MANE?
As of Sep 30, 2026, MANE has 4.24M shares short and 4.7 days to cover.
What exchange is MANE listed on?
Veradermics, Incorporated (MANE) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of MANE with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MANE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.